TETRABENACINE TREATMENT IN PERSISTING DYSKINESIA CAUSED BY PSYCHOPHARMACA
Abstract
In 3 patients suffering from schizophrenia and one patient with arteriosclerotic dementia persisting dyskinetic movements caused by psychopharmaca disappeared almost or completely after treatment with tetrabenacine (Nitoman®). The schizophrenics received a daily dose of 75 mg., whereas it was necessary to give the patient with dementia 150-300 mg. per day in order to obtain a satisfactory effect. This patient responded by developing a certain degree of drowsiness, while no side effects were observed in the other cases.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
